Skip to main content
Premium Trial:

Request an Annual Quote

Benjamin Reed, James Fullerton-Batten, Nick Ash, Matt Pomroy

Epistem has completed its board appointments: Benjamin Reed will join as commercial director — he had previously served as Epistem's pharmacogenomics business development director; James Fullerton-Batten joins the board from Concept Life Sciences, where he served as finance director; Nick Ash joins the board from Source BioScience, where he served as CEO; and Matt Pomroy joins the board as a non-executive investor representative from Foresight Group.


The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.